Delivering innovative diagnostic cancer tests
FacebookTwitterLinkedin

Chronix notes abstract disclosure for forthcoming ASCO presentation. Head and neck cancer study finds CNI score to be a stronger predictor of time to recurrence than current method based on lymph node invasion.

The poster presentation is entitled Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer.

It presents data from a study that examined copy number instability (CNI) in circulating tumour DNA from 54 patients undergoing surgery for head and neck cancer and compared the Chronix CNI-based test as a predictor of time to progression with the current method based on the degree of tumour invasion of lymph nodes (pN status).

By | May 18th, 2017|Chronix news|0 Comments
Read More

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

By | May 15th, 2017|Peer-reviewed medical publications|0 Comments
Read More

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

By | May 14th, 2017|Peer-reviewed medical publications|0 Comments
Read More

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | May 13th, 2017|Peer-reviewed medical publications|0 Comments
Read More

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | May 12th, 2017|Peer-reviewed medical publications|0 Comments
Read More

HPV Genotyping and Treatment Outcome Predictions

Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).

The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.

By | May 10th, 2017|Peer-reviewed medical publications|0 Comments
Read More

Breast Cancer Liquid Biopsy Screening Test

Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).

Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.

By | May 9th, 2017|Peer-reviewed medical publications|0 Comments
Read More

Animal Model for MRD in Breast Cancer

Beck, J. et al. Structural variation in mammary carcinomas and their detection in cell-free plasma DNA. PLOS One 2013 (10.1371/journal.pone.0075485).

Mammary tumors are the most frequent cancers in female dogs exhibiting a variety of histopathological differences. There is lack of knowledge about the genomes of these common dog tumors. Five tumors of three different histological subtypes were evaluated.

By | May 8th, 2017|Peer-reviewed medical publications|0 Comments
Read More

Digital PCR of cfDNA for Transplant Rejetion

Beck J. et alDigital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 ;59:1732-41

Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA.

By | May 7th, 2017|Peer-reviewed medical publications|0 Comments
Read More

NGS of prostate cancer

Schütz, E. et al. Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. J ClinOncol 28:15s, 2010 (suppl; abstr 10505).

The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology.

By | May 6th, 2017|Peer-reviewed medical publications|0 Comments
Read More